













grade, pathological stage, etc., and treatment 
has often been based on single-institution 
retrospective experience. These studies have 
commonly ignored potentially modifiable 
clinical factors, structures and processes that 
are measured by their association with 
morbidity, mortality and length of stay (LOS). 
One of the recognized fathers of quality of 
care initiates, Avedis Donabedian, was a 
Professor of Public Health at the University 
of Michigan for many years. He described 
quality of care through three components, i.e. 
structure, process and outcomes [2]. Structure 
is related to the support from the system and 
includes hospital equipment and support, 
training of individual surgeons, and patient 
volume of an individual surgeon or hospital. 
Process, on the other hand, relates to the 
actual care provided and usually relies on 
evidence-based medicine (e.g. prophylaxis 
for deep vein thrombosis). Unfortunately, 
in urology there are few data on specific 
process measures that are known to make 
a difference. The most commonly used 
measure of quality is outcome, which is 
reflected by morbidity, complication rates, 
mortality rate, functional health outcomes 
commonly referred to now as ‘quality-of-life 
assessments’, patient satisfaction evaluations, 
and costs. Urologists have previously not 





viewpoint; unfortunately, they have often 
focused on one set of outcome measures, 
which are those most easily obtained from a 
retrospective chart analysis.
A good example to examine for quality of care 
in urology is a radical cystectomy for bladder 
cancer. The contemporary perioperative 
mortality and morbidity rates are 
substantially better than in earlier decades, 









3%. This improvement in 
care can be credited to improvements in 
surgical and anaesthetic techniques, with 
better perioperative management, including 
nutritional support. Morbidity is a common 
cause for prolonged LOS and resource 
consumption by hospitals. For radical 
cystectomy the median LOS is highly variable, 
at 8–14 days in most recent series.
One approach to evaluating quality is the 
National Surgical Quality Improvement 
Program (NSQIP), which started in 1991 at 
124 Veterans Administration (VA) Hospitals in 
the USA. This programme includes prospective 
data collection by well-trained nurse 
reviewers, who use standardized definitions 
of the variables to be collected. There is also 
rigorous inter-rater reliability and a validated 
risk-adjustment model. In addition, there are 
standardized endpoints established within the 
30-day morbidity and mortality evaluation. 
This programme now has data on more than 
one million cases. More recently, there has 
been an expansion of this method into non-
VA academic medical centres. The academic 
pilot project focused on three institutions 
(University of Kentucky, University of 
Michigan, and Emory University) and has now 
been expanded into 14 academic centres. The 
method has been validated and found to be as 
reliable in the academic setting as it was 
in the VA system. In general, the observed/
expected outcomes are similar between the 
VA and non-VA hospitals, after case-mix 
adjustment. The latter is an extremely 
important component of such prospective 
studies. Unfortunately, many earlier 
assessments by payer groups looked only at 
raw data without considering risk adjustment. 
This frequently gave a flawed evaluation of 
the quality of care provided. For example, the 
NSQIP data for surgery is evaluated by the 
observed/expected ratio of events to allow 
 







Urology, University of Michigan, Ann Arbor, MI, USA
Quality of care is now being measured for 
many surgical procedures. The coronary 
bypass is probably the first surgical procedure 
to be investigated in depth because of its high 
profile. The more recent development is that 
‘perceived’ quality is being translated into 
action by payers and consumers, either by 
selecting providers to participate in a 
programme or by an enhanced payment 
system. Pilot projects to reward ‘quality’ are 
being initiated by both private and 
governmental insurance programmes. In my 
opinion, the field of urology has lagged 
behind other surgical and medical specialities 
in addressing the quality issues of urological 
practice.
There are recent noteworthy articles in both 
the medical and lay press. In July 2003, 
Sternberg [1] suggested in an editorial that 
“. . . quality of care should be measured and 
reported routinely at both the national and 
provider-specific, i.e. hospital and physician 
levels.” In 
 
The Wall Street Journal
 
 on March 
25, 2004, an article described plans for a 
consortium of 28 large employers to develop 
‘score cards’ to help employees to choose 
doctors, based on how well they care for 
patients and how cost-efficient they are. The 
Leapfrog Group, a coalition of public and 
private organizations that provides health 
care benefits (e.g. organizations ranging from 
the Board of Pensions of the Presbyterian 
Church, USA, to the Washington State Health 
Care Authority, to General Motors 
Corporation), has established standards for 
patient safety, and rewards providers or 
hospitals for best performances. Thus, there is 
no doubt that quality of care at both the 
hospital and individual physician level is 
going to be measured closely, and the 
resulting data will translate into higher 
payments for the best performers.
Unfortunately, there are still major gaps in 
knowledge about quality of care. Historically, 
the focus has been on disease-specific 
factors; in oncology this relates to tumour 
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comparisons among hospitals. The hospitals 
were initially ranked by unadjusted mortality 
rate. When the rank was altered by risk 
adjustment, the mortality rate commonly 
changed and several of the hospitals that 
were perceived as the best had a much less 
favourable rating after risk adjustment. 
Conversely, some hospitals that appeared not 
to do well improved substantially after risk 
adjustment, showing that they probably 
operated on patients with more complex 
problems.
To apply this method to a urology dataset our 
group examined 2538 radical cystectomies 
performed between 1991 and 2000. The cases 





100 clinical, operative and outcome 
variables. The study examined several 
outcomes. The 30-day mortality rate was 
2.9%, comparable with most other 
retrospective and single-institution series. 
Notably the 90-day mortality rate was 6.8%, 
higher than commonly appreciated. A greater 
LOS or complication rate was associated with: 
(i) dependent functional status; (ii) elevated 
creatinine*; (iii) lower albumin*; (iv) longer 
operative duration*; (v) perioperative blood 
transfusion requirements*; (vi) age; (vii) ASA 
status; (viii) smoking history*; and/or (ix) 
surgeon experience*. The asterisk refers to 
circumstances that are potentially modifiable 
by improvements in structure or process. For 
example, it may be possible to decrease LOS or 
complication rates by improving renal 
function by relieving obstruction, improving 
preoperative nutritional status, or by ensuring 
optimal pulmonary function by having the 
patients stop smoking before surgery. Longer 
operative time, perioperative blood 
transfusion requirements, and surgeon 
experience are all interrelated to the volume 
of procedures done by the surgical team. The 
relationship between a higher volume of 
cases and better outcome in other complex 
surgical procedures such as esophagectomy 
or the Whipple procedure emphasizes concern 
that the surgeon who only does an occasional 
large case may have a higher complication 
rate.
The most important aspect of both the earlier 
NSQIP studies and our evaluation of 
cystectomy will be to more closely examine 
the data. The NSQIP annual report allows an 
examination of the observed/expected 
mortality ratios for all operations by hospitals. 
It is clear that some hospitals performed 
statistically better than the norm, while 
others were worse. Rather than a reward or 
punitive action, investigations focused on 
how to understand what activities took place 
in the hospitals that performed well, 
compared with those that were worse. This 
may allow a transfer of practices and 
procedures to the hospitals that did not 
perform as well, to ultimately improve their 
performance.
What does the speciality of urology do next to 
evaluate quality of care? First of all, in this era 





 as well as quality. Value is 
defined as quality/cost. No healthcare system 
is currently able to ignore cost issues. It 
is my opinion that our academic centres in 
urology are far behind other specialities. 
Unfortunately, the AUA does not have specific 
quality-of-care initiatives. However, an AUA 
Quality of Care and Patient Safety Committee 
has recently been formed to investigate these 
areas. In addition, there are several pilot 
programmes through governmental agencies 
or consortiums of payers and individual 
hospitals or groups of hospitals. We should all 
support these pilot programmes. We are 
probably much better off both as a speciality 
and as individuals to participate in the 
development of quality-of-care standards, 
rather than to react negatively once they are 
established. In urology we will also need a 
cohort of well-trained urologists to lead these 
efforts in health services research and quality 
of care. There are established programmes 
through the Robert Wood Johnson 
Foundation and National Institutes of Health 
Training Grants, at centres such as University 
of California at Los Angeles and the University 
of Michigan, to train young individuals for 
careers as physician-scientists in the field of 
health services research.
The lead investigators in the NSQIP 
Cystectomy Project at the University of 
Michigan are Drs Brent Hollenbeck and John 
Wei. Other members of the investigative team 
at the University include: Drs Willie 
Underwood, David Miller, David Taub, Darrel 
Campbell, John Birkmeyer, and Rod Dunn. 
Individuals at the NSQIP Central Office 









Improving the quality of 
care- can we practice what we preach? 
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Measuring the quality of surgical care: 
structure, process, or outcomes? 
 




















The Institute of Urology, 
University College London, and The Royal Marsden Hospital, London, UK
The human bladder has a great many failings; 
however, it remains the best means that we 
have of storing and evacuating urine. All the 
substitutes are much worse. Urologists should 
always attempt to conserve the natural lower 
urinary tract.
When a replacement is needed it is useful 
to think of three separate components; a 
reservoir, a sphincter mechanism and a 
conduit to the exterior. There are many 
published reports of complete replacement 
systems but there are great differences 
among patients, and many have requirements 
that make an ‘off the shelf’ reconstruction 
inappropriate. The reconstructive surgeon 
must be the master of all of the components 
of lower tract replacement and select a 
system that is suitable for each individual.
The use of the rectum as a reservoir, the anal 
sphincters as a control mechanism, and the 
anus as a conduit, has a long and mainly 
dishonourable history. The much cited original 
description of the ureterosigmoidostomy 
by Simon in 1852 [1] was a report of the 
postmortem on his one patient. The literature 
of the first quarter of the last century records 
the legion of complications and deaths that 
accompanied this operation. It is ironic that 
just as the pathophysiology was becoming 
understood, the ileal conduit arrived and 
 








dominated the diversion ‘market’ for 
25 years.
So why is diversion into the rectum having its 
renaissance? There are two main reasons. The 
first is that Hohenfellner and Ghoneim, 
independently, recognized that which should 
have been obvious to all, i.e. that the pressure 
in the rectum had to be reduced. The second is 
that it has become apparent that all of the 
other lower tract replacements also have high 
complication rates.
Within all of the named systems of diversion 
and reconstruction, there are four broad 
categories; the conduit dripping into an 
external appliance, the orthotopic neobladder, 
the suprapubic continent catheterizable 
diversion, and the rectal pouch.
Published reports extol the virtues of the 
authors’ favourite methods but give little 
guidance on the relative merits of each. There 
is a high degree of bias and lack of valid 
comparative data. The place of the rectal 
pouch can therefore only be decided on the 
basis of the perceived advantages and 
complications.
The present author’s preferred variation on 
the rectal pouch is the Mainz II [2]. In this 
operation, 10 cm of rectum and 10 cm of 
lower sigmoid are detubularized and sutured 
together to form a pouch. In this respect it is 
similar to the other reservoirs made from 
large bowel. The ureters are then tunnelled 
into the bowel wall in a traditional manner. 
The slurry of urine and stool is passed through 
the anus.
It has the virtue of simplicity, especially after a 
radical cystectomy; the ureters and the 
rectum are just next to each other and 
waiting to be joined together. No re-packing 
of the intestines is needed and there is no 
intestinal anastomosis. It takes the same time 
to perform as an ileal conduit and is nearly an 
hour quicker than a continent suprapubic 
diversion.
The consequences and complications are, of 
course, legion. On the positive side, the 
patient evacuates in a reasonably natural 
manner at intervals similar to normal bladder 
emptying. Although the slurry is clearly 
different from stool, the patient does not have 
to learn a new technique. Clean intermittent 
self-catheterization is never needed. There are 
no appliances. The commonest metabolic 
complication, hyperchloraemic acidosis (HCA) 
is easy to detect and cheap to treat. Infective 
complications are rare. There is a very small 
risk of upper tract infection or stones. There 
are no reports of pouch stones or rupture.
On the negative side, the slurry does have 
an offensive, ammoniacal smell. It is not 
a very practical diversion for a patient 
living in a small, crowded apartment with 
only one lavatory. The risk of incontinence is 
0–8%.
The incidence of HCA is uncertain. The risk 
seems to be cumulative with time and the 
follow-up of such patients is relatively short. 
If there is an analogy with the conventional 
ureterosigmoidostomy, it will be 50% at 10 
years. It should not be used in patients who 
have had pelvic radiotherapy.
The most worrisome complication is 
anastomotic neoplasm. This tumour occurs at 
the reservoir/ureteric junction. It is thought to 
be a result of the mixture of urine and stool in 
contact with such an anastomosis. There are 
no reports of this condition in the Mainz II 
to date. However, in the conventional 
ureterosigmoidostomy, the incidence is 22% 
at 20 years of follow-up [3]. The tumours are 
adenomatous. Initially they are benign and 
appear to become malignant in a mean of 
5 years. The earliest reported tumour is at 
12 years from the formation of the 
ureterosigmoidostomy, and surveillance by 
flexible sigmoidoscopy is essential from about 
10 years onwards. In patients having a 
cystectomy for cancer, this complication may 
not be relevant, but in young patients it is of 
critical importance.
Should the Mainz II prove unacceptable to the 
patient for any reason, the surgery to get rid 
of it is formidable. It is difficult to re-
tubularize the pouch back into a rectum and 
sigmoid. It is possible to convert the pouch 
part into a reservoir for self-catheterization 
and anastomose the upper sigmoid to the 
lower rectum to restore bowel function. 
Obviously the pouch can be resected 
altogether. A covering colostomy may be 
needed. I do not know whether the pouch can 
just be abandoned and used as a capacious 
rectum for stool, with the urine diverted into 
a conduit; the low intrinsic pressure would 
probably lead to intractable constipation.
Apart from the surgical issues, the patients 
will be particularly interested in the quality of 
life. Here there are no reports; many authors 
state that the outcome of the operation is 
acceptable. It is seldom said to whom it was 
acceptable or by what criteria. We are left 
with the impression that it is acceptable to 
the surgeon.
Very few patients have experienced two 
successful bladder replacements. If a 
patient has an unsatisfactory diversion, 
another type may have a better outcome 
but does not provide a valid comparison. 
In my practice there is a small group of 
patients who had a successful conventional 
ureterosigmoidostomy in childhood 30 or 
more years ago. They are, apparently, happy 
with their lot. In 13 there has been an 
anastomotic neoplasm. None of these 
patients has volunteered to have an 
alternative diversion. All have wished to 
have the tumour resected and a new 
ureterosigmoidostomy formed. In two 
patients in whom this was not possible, a 
catheterizable pouch was made and both 
have expressed their dissatisfaction. It would 
seem that even having experienced the most 
serious complication, the patients preferred 
the ureterosigmoidostomy to any alternative.
The other replacements of the lower urinary 
tract also have their advantages and 
disadvantages. The incidence and importance 
is variable among the reports of different 
authors. It is not possible to say whether 
those of the Mainz II are better or worse. For 
each patient, the best that can be offered is a 
realistic appraisal of the options and allow a 
personal decision.
The augmented rectal pouch is an option for 
lower tract replacement that is just as valid as 
any other. It has a pattern of advantages and 
disadvantages that is no worse than any 
other. To me it seems preferable to an ileal 
conduit or a continent catheterizable 
diversion. It seems on a par with an 
orthotopic neobladder and under some 








Ectopia vescicae (absence of the 
anterior walls of the bladder and pubic 
abdominal parietes): operation for 
directing the orifices of the ureters into 
the rectum; temporary success; 
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BICALUTAMIDE 150 mg: PRACTICAL PRESCRIBING IN PATIENTS 







Urology, Royal Hallamshire Hospital, Sheffield, UK
The licensed indication for bicalutamide 
150 mg has recently changed in the UK 
and several other countries. In the UK, 
bicalutamide 150 mg is indicated as an 
alternative to castration for patients with 
locally advanced prostate cancer, either alone 
or as an adjuvant therapy; it is no longer 
indicated in patients with localized disease 
who would normally be managed by 
observation. Whilst it would be unusual to 
commence hormone treatment in patients 
with clinically localized prostate cancer who 
would otherwise undergo watchful waiting, 
there nevertheless remains a degree of 
uncertainty within the clinical community 
about which patients should and should not 
be considered for bicalutamide 150 mg. This 
article reviews the conclusions of the most 
recent analysis of the bicalutamide Early 
Prostate Cancer (EPC) programme that have 
led to the changes in the license for 
prescribing bicalutamide 150 mg, and 
considers their clinical implications.
The ongoing EPC programme is the world’s 





8000 patients [1]. Initiated in 1996, 
it consists of three complementary 
randomized, double-blind, placebo-controlled 
trials examining whether adding bicalutamide 
150 mg/day to standard care (be it radical 
prostatectomy, radiotherapy or watchful 
waiting) can reduce the risk of prostate cancer 
progression and improve overall survival in 
patients with localized or locally advanced 
disease.
The latest analysis of the EPC programme 
data, in 2003 at a median of 5.4 years of 
follow-up [2], confirmed previous findings [3] 
that bicalutamide 150 mg significantly delays 








 0.001) [2] and prolongs the time to PSA 








 0.001) [4] compared with 
standard care alone. The greatest benefit was 
in patients at highest risk of progression. 
Given the relatively early stage of the study, it 
is hardly surprising that in the overall results 
there was no difference in survival between 
patients receiving placebo or bicalutamide 








 0.58; 15% mortality) [2].
Further exploratory analyses, beyond the 
remit of the original protocol, revealed no 
difference in survival across all subgroups, 
except in those patients managed by 
observation. Within the watchful-waiting 
subgroup, with bicalutamide 150 mg there 
was a small trend toward reduced survival in 
patients with localized disease (HR 1.23; 95% 
CI 1.00–1.50) but a small trend toward 
prolonged survival in patients with locally 
advanced disease (HR 0.81; 95% CI 0.63–1.04) 
compared with observation alone [5]. The 
reduction in deaths in patients with locally 
advanced disease receiving bicalutamide was 
driven by a reduction in prostate cancer 
mortality. The increased deaths in patients 
with localized disease receiving bicalutamide 
was caused by a relative increase in deaths 
related to causes other than prostate cancer, 
which appear unrelated to any one specific 
cause [5].
So who should be considered for bicalutamide 
150 mg therapy? The latest results from the 
EPC programme have shown that the greatest 
progression-free survival benefits for this 
treatment are in patients with locally 
advanced disease. As such patients are at 
significant risk of disease progression, any 
additional therapies that can reduce this risk, 
with minimal effects on lifestyle, are 
important.
The standard care for patients with locally 
advanced disease is often external-beam 
radiotherapy and, in this setting, the EPC 
programme data show that adding 
bicalutamide 150 mg as adjuvant therapy 
significantly reduces the risk of disease 








 0.0035) [6]. 
Furthermore, many patients with clinically 
localized disease who have had a radical 
prostatectomy are re-staged by the 
pathologist to pT3, or locally advanced 
disease, and here again adjuvant bicalutamide 
150 mg significantly reduced the risk of 








 0.0034) [7]. 
Patients with locally advanced disease are 
not always suitable for, or opt not to receive, 
local therapy; under these circumstances, 
bicalutamide 150 mg again showed a 
significant risk reduction in terms of disease 
progression compared with observation 








 0.001) [5]. Moreover, as 
bicalutamide 150 mg has important quality-
of-life advantages over castration, in terms of 
maintaining libido, allowing better physical 
activity and preserving normal bone mineral 
density [8,9], it offers an attractive alternative 
to androgen deprivation by surgical or 
medical castration.
In summary, the EPC programme continues to 
show, at a median of 5.4 years of follow-up, 
that bicalutamide 150 mg provides an 
important clinical benefit for patients with 
prostate cancer by reducing the risk of disease 
progression for those with locally advanced 
disease. It will be important to see whether 
these clinical benefits are maintained over 
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Bicalutamide 150 mg 
alone or as adjuvant to standard care 
significantly improves progression-free 
survival in patients with early, non-
metastatic prostate cancer (median 

















Bicalutamide as immediate therapy either 
alone or as adjuvant to standard care of 
patients with localized or locally advanced 
prostate cancer: first analysis of the Early 

























Bicalutamide 150 mg in addition to 
standard care significantly improves 
prostate-specific antigen progression-
free survival in patients with early, 
non-metastatic prostate cancer: median 

















Bicalutamide (‘Casodex’) 150 mg in 
addition to watchful waiting in patients 
with early non-metastatic prostate 
cancer: updated analysis at a median 

















Bicalutamide (‘Casodex’) 150 mg as 
adjuvant to radiotherapy significantly 
improves progression-free survival in 
early non-metastatic prostate cancer: 
results from the bicalutamide early 
prostate cancer programme after a 

















behalf of the ‘Casodex’ Early Prostate 
Cancer Trialists’ Group. Bicalutamide 
(‘Casodex’) 150 mg as adjuvant to radical 
prostatectomy significantly increases 
progression-free survival in patients with 
early non-metastatic prostate cancer: 















Treatment of prostate 















The role of antiandrogen 















SUPPRESSOR SCREENING – A POTENTIAL NEW MODEL FOR 







St Anthony’s Hospital, Surrey, UK
For centuries our energies have been 
channelled into finding the causes of disease 
processes; the reason for this is obviously to 
satisfy the quest for knowledge and to link 
cure or treatment of disease process to the 
cause. The concept of suppressor screening is 
a novel approach in genetics, which aims to 
identify directly the genes which provide a 
cure to a certain condition rather than 
identifying the genes which cause the 
condition.
A typical scientific model for studying a 
disease process involves three main steps. 
First, the aim is to find an animal (e.g. a strain 
of mouse or rabbit) that develops the disease 
process, or to find a way of triggering the 
disease process in the same animal. This is 
followed by a study of the mechanism and 
understanding of the disease as it develops. 
Finally, a drug is designed to treat the 
condition. This is a simplistic model but many 
studies fit this basic pattern. However, the 
causative mechanism can be bypassed and 
the result created in a group of genetically 
manufactured organisms in which the disease 
process tends to be reproduced. These 
organisms can then be studied to see which 
genes protect against the development of the 
disease process.




 [1], in which genetic screens in mice, 
particularly those that identify modifiers of 
pre-existing genetic defects, have been used 
successfully to order components of complex 
signalling pathways. An agent that causes 
random mutations was injected into 
hundreds of mice with a genetic defect that 
causes thrombocytopaenia. Thousands of 
direct offspring were then screened to reveal 
seven healthy mice. These were then studied 
to reveal one of three different potential 
mutations, which could cure the disease. In 
theory, targeted drugs for the protein coded 
for by the normal gene could potentially cure 
thrombocytopaenia.
This model could be exploited in urological 
diseases. The PAC120 xenograft is a relatively 
new model of hormone-dependent prostate 
cancer, providing an opportunity to study the 
hormone-dependence escape mechanism and 
to evaluate the efficacy of new therapeutics 
[2]. This model of suppressor screening can be 
used in xenografted mice to decipher which 
genes protect against hormone escape in 
prostate cancer, or indeed the development of 
the disease itself.
The Eker rat model of hereditary renal 
carcinoma is an example of a Mendelian 
dominantly inherited predisposition to a 
specific cancer in an experimental animal. 
Forty years after the discovery of the Eker rat 




 [3] and Knudson’s group 
[4] independently identified a germline 
retrotransposon insertion in the rat 
homologue of the human tuberous sclerosis 
(TSC2) gene. This was perhaps the first 
isolation of a Mendelian dominantly 
predisposing cancer gene in a naturally 
occurring animal model. This rat was named 
the ‘Nihon’ rat and its predisposing (Nihon) 
gene could be a novel renal tumour-
suppressor gene. A new hereditary renal 
carcinoma in the rat was subsequently found. 
Mass ‘grooming’ of such rats will produce 
renal cancer in each subsequent reproductive 
population. The model of suppressor 
screening can then be applied to look at the 
few rats that do not develop the malignancy, 
and these mice selectively tested for genes 
that may have rendered them immune to 
developing the malignancy. The extrapolation 
of this concept to humans may be in its 
infancy, but can be envisaged in the near 
future.
Currently there is good epidemiological 
evidence for prostate cancer susceptibility 
genes, but no major locus has been 
unequivocally identified. A genome-wide 
search was conducted from an international 
consortium (ACTANE) [5]. About 90% of the 
prostate cancers identified in this study were 
clinically detected. Eight loci with preliminary 





have been identified. Genetic susceptibility to 
prostate cancer is likely to be controlled by 
many loci, with no single gene explaining a 
large fraction of the familial risk. One way of 
identifying prostate cancer susceptibility 
genes is to extrapolate the concept of 
suppressor screening to the human model 
or using xenografted PAC120 mice.
An example of the extrapolated applicability 
of this approach in understanding urological 




 [6], where 
there were mucinous differentiation features 
associated with hormonal escape in a human 
prostate cancer xenograft. Using PAC120 
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and its hormone-independent variants, the 
expression of mucins (e.g. MUC1 and MUC2) 
were analysed by immunohistochemistry 
or RT-PCR. The resulting data indicated 
mucinous differentiation as an important step 
in acquiring hormone independence in this 
cancer, and suggested that secretory mucins 
might participate in an unknown pathway of 
hormonal escape in prostate cancer.
The technique of suppressor screening has 
been described previously and used to study 
the biological function of fruit flies and 
worms. It has not been exploited in 
vertebrates and its potential for finding cures 
is one that should be explored further in 
urological malignancies. This model has the 
potential to accelerate the understanding of 
disease processes. Approaches such as the 
one described not only help in understanding 
disease processes but also may potentially do 
so at an exponential rate. It has specific 
advantages in researching conditions such as 
prostate cancer in which disease progression 




















Myb mutation causes supraphysiological 
production of platelets in the absence of 
thrombopoietin signaling. 
 















 A new model of human 
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Predisposition to renal 
carcinoma in the Eker rat is determined by 
germ-line mutation of the tuberous 
sclerosis 2 (TSC2) gene. 
 















of a genome-wide linkage analysis in 
prostate cancer families ascertained 

















Mucinous differentiation features 
associated with hormonal escape in a 
human prostate cancer xenograft. 
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